Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 562

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 562
---
-------------------------------|:--|----:|:--|:--|:--|:-----|:--|------:|:--|:--|:--|:---------|:--|:-----|:--|:--|
| Cost of Goods Sold | ​ | ​ | ​                               | $ | — | ​ | ​ | ​ | ​    | $ | 1,558 | ​ | ​ | ​ | ​        | ​ | -100% | ​ | ​ | ​ | ​                              | $ | 620 | ​ | ​ | ​ | ​    | $ | 5,566 | ​ | ​ | ​ | ​        | ​ | -89% | ​ | ​ |

There were no COGS recorded for the three months ended September 30, 2024 as there were no commercial sales during the period. Cara recorded COGS of $1.6 million for the three months ended September 30, 2023, and $0.6 million and $5.6 million for the nine months ended September 30, 2024 and 2023, respectively, which were related to Cara’s commercial supply revenue for KORSUVA injection sales to CSL Vifor for these periods. Research and Development Expense

| ​                                                 
 ​                                                 
 ​                                                 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months EndedSeptember 30, 
 2024                            
 Dollar amounts in thousands     |   |       |   | ​ | ​ | 2023 |   |        |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​     
 ​     | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 Dollar amounts in thousands    |   |        |   | ​ | ​ | 2023 |   |        |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​    
 ​    | ​ 
 ​ | ​ 
 ​ 
 ​ |
|:--------------------------------------------------|:--|:--|:--------------------------------|:--|------:|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:---------|:--|:------|:--|:--|:--|:-------------------------------|: